U.S. Markets open in 1 hr 58 mins

Osiris Misses on Q4 Earnings

Zacks Equity Research

Osiris Therapeutics Inc.’s (OSIR) fourth quarter 2013 earnings came in at 11 cents per share, compared to the year-ago loss of 2 cents per share. However, fourth quarter earnings missed the Zacks Consensus Estimate of $1.29 per share.

Revenues for the quarter came in at $8.1 million, missing the Zacks Consensus Estimate of $58 million but well above the year-ago quarter revenues of $2.9 million.

Full year earnings came in at 3 cents per share, compared to the year-ago loss of 18 cents per share and the Zacks Consensus Estimate of a loss of 21 cents per share. Revenues came in at $24.3 million, well above the year-ago revenues of $7.8 million. The Zacks Consensus Estimate was $73 million.

Quarterly Details

Research and development (R&D) expenses increased 62.4% from the year-ago period to $1.9 million. The company intends to study Grafix for the treatment of venous leg ulcers.

Selling, general and administrative expenses increased to $4.1 million from $1.7 million in the year-ago period reflecting investment in commercial activities. The company has increased its sales force significantly for the promotion of Grafix.

Meanwhile, in early Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal (for up to $100 million) to a wholly-owned subsidiary of Mesoblast Limited. Osiris will be entitled to royalty payments as well.

Osiris also stated that the FDA does not require the company to file a biologic license application (:BLA) for Grafix to remain on the market. However, the company intends to submit a BLA for enhanced label claims – discussions with the FDA are ongoing.

Osiris is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include companies like Alexion Pharmaceuticals, Inc. (ALXN), Gilead Sciences Inc. (GILD) and Alkermes plc (ALKS) - all three are Zacks Rank #1 (Strong Buy) stocks.

Read the Full Research Report on ALXN
Read the Full Research Report on ALKS
Read the Full Research Report on GILD
Read the Full Research Report on OSIR


Zacks Investment Research